Reply to "NeoADAURA: Can We Afford to Overlook Objective Response Rates?" and "Is Major Pathologic Response the Best

Jamie E Chaft1, Masahiro Tsuboi1, Walter Weder1

  • 1Jamie E. Chaft, MD, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, Department of Medicine, Weill Cornell Medical College, New York, NY, Masahiro Tsuboi, MD, Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Walter Weder, MD, Department of Thoracic Surgery, University of Zurich, Thoracic Surgery, Clinic Bethanien, Zurich, Switzerland.

Summary

No abstract available in PubMed .